Head and Neck Squamous Cell Carcinoma Reagents

HNSCC is strongly associated with HPV infection (oropharyngeal) and tobacco/alcohol exposure (non-HPV). EGFR remains the only approved targeted therapy, while PD-1 checkpoint blockade has become first-line for recurrent/metastatic disease. abinScience provides reagents for EGFR, PD-L1, HPV/p16, TROP2, Nectin-4, and B7-H3. RUO

Key Biomarkers & Targets

EGFR

ErbB1 / HER1

Overexpressed in >90% of HNSCC; cetuximab target. 180+ antibodies and biosimilar-grade reference proteins.

Antibodies • Proteins • Biosimilars

PD-1 / PD-L1

CD279 / CD274

Pembrolizumab first-line for PD-L1 CPS ≥1 HNSCC. 260+ combined checkpoint antibodies and proteins.

Antibodies • Proteins • Biosimilars

HPV / p16

HPV-Driven Oropharyngeal

HPV-positive HNSCC has distinct biology and better prognosis. p16 IHC is the clinical surrogate for HPV status. 190+ combined products.

Antibodies • Proteins

TROP2 / Nectin-4

ADC Targets

Emerging ADC targets in HNSCC following success in other epithelial cancers. 50+ combined antibodies and biosimilar proteins.

Antibodies • Proteins • Biosimilars

B7-H3 / CD276

Immune Checkpoint

Overexpressed in HNSCC; emerging target for ADCs and checkpoint therapy. 41 antibodies and biosimilar proteins.

Antibodies • Biosimilars

p63 / CK5/14

Squamous Differentiation

Diagnostic IHC markers for confirming squamous cell origin in poorly differentiated head and neck tumors.

Antibodies

Why Researchers Choose abinScience for HNSCC

EGFR & Cetuximab ComparabilityAnti-EGFR antibodies and biosimilar-grade cetuximab reference proteins for binding, ADCC, and potency testing in HNSCC-derived models.

HPV Status AssessmentHPV L1/E6/E7 antibodies and p16/CDKN2A antibodies for IHC-based HPV status determination in oropharyngeal cancer specimens.

Next-Gen ADC TargetsTROP2, Nectin-4, and B7-H3/CD276 reagents for emerging ADC and bispecific antibody programs targeting HNSCC.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

HPV-positive vs. HPV-negative stratification: Apply p16/CDKN2A IHC antibodies as a surrogate for HPV status in oropharyngeal cancer, complemented by HPV E6/E7 antibodies for confirmatory testing.
PD-L1 CPS scoring: Use anti-PD-L1 antibodies for research-use IHC to assess Combined Positive Score (CPS) for immunotherapy eligibility studies in HNSCC cohorts.
EGFR-targeted therapy development: Recombinant EGFR-ECD proteins and biosimilar cetuximab for binding kinetics, epitope mapping, and cell-based ADCC assays in HNSCC cell lines.
Squamous differentiation panel: p63, CK5/6, and CK14 antibodies available for squamous differentiation research. See product pages for validated applications.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which p16 antibodies work for HPV status IHC?

Anti-p16/CDKN2A antibodies available. See product pages for validated applications. Research use only.

Do you carry EGFR biosimilar reference proteins?

Yes. Research-grade cetuximab and panitumumab biosimilar proteins with ELISA, FACS, and Functional assay validation.

What B7-H3 reagents are available?

Anti-B7-H3/CD276 antibodies and research-grade biosimilar proteins available. See product pages for validated applications.

Do you offer multiplex IHC panels for HNSCC?

We provide individual validated antibodies for PD-L1, CD8, CD68, p16, and EGFR that can be combined in sequential or multiplex IHC workflows. Contact us for panel design guidance.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.